Chinese scientists discover new drugs for treating coronary artery disease

On May 10, the new crown treatment drug discovered by Chinese scientists was granted the national invention patent. Patent Description, 10 μ M (μ mol / L) stephanine inhibited coronavirus replication by 15393 times.

What does a figure more than 15000 times represent? On May 12, the reporter of science and technology daily interviewed Professor tongyigang, the inventor of this patent and Dean of School of life science and technology of Beijing University of chemical technology.

"Generally speaking, this figure can be understood as that if there are 15393 viruses without stephanine drugs, 10 μ In the case of M stephanine drug, the number of viruses will be only 1. In other words, a small amount of stephanine can prevent the expansion and spread of novel coronavirus. "

Tongyigang said that according to the current research data, the drug's ability to inhibit novel coronavirus ranked high among all novel coronavirus inhibitors found in humans. American scholars have also previously published papers in science to confirm that the data of stephanine is outstanding among the 26 drugs they studied, and is better than those of redcivir and palovide that have been approved for marketing.

Tongyigang said that in February, 2020, the team originally found that stephanine had strong anti novel coronavirus activity. The relevant papers published in March of the same year have now become the highly cited papers of ESI.

For more than two years, Tong Yigang has further cooperated with Professor zhaojincun and Professor shizhengli, academician Zhongnanshan, to verify the anti novel coronavirus effect of stephanine with novel coronavirus, and confirmed the anti novel coronavirus effect of the drug.

"Our country was the first to discover the anti crown effect of stephanine, and the research has also been supported by the Ministry of science and technology, Beijing Municipality, the Ministry of education and other projects." Tongyigang said that the patent authorization will help to carry out further clinical trials and research. At present, a Canadian pharmaceutical enterprise has contacted the US FDA to carry out clinical trials and Research on the treatment of COVID-19 with stephanine. It is expected that the clinical trials will be formally launched in the second half of this year.

Source: Science and Technology Daily

Editor: guochunyan

[source: Zhong'an online]